In a large double-blind study, Radboud university medical center researchers show that patients in the early stages of Parkinson's disease can exercise regularly at home for 6 months. This regular exercise has a positive effect on their motor disability comparable to the effect of conventional Parkinson's medication. The article was recently published in The Lancet Neurology.
Even though exercise is known to be healthy, many people find it difficult to maintain an exercise program for a longer time. This applies even more to people with a chronic illness such as Parkinson's disease, where physical and mental limitations are additional obstacles.
The Park-in-Shape study, funded by ZonMW (Netherlands Organization for Health Research & Development), tested an innovative solution for this challenge. The participants were divided into two groups. Both groups had a motivational app at their disposal, which offered the participants rewards for exercising. The control group only performed stretching exercises, while the active intervention group was instructed to exercise for 30-45 minutes on a stationary bicycle at home, at least three times a week.
Racing against othersThe active group's exercise bikes were also equipped with motivating games, making the program more entertaining and challenging for the participants. For example, the participants could race against their own previous performance - a "ghost rider" – or against a group of other cyclists. The system adjusted the difficulty of the game to the patient's heartbeat, making the challenge just right. The challenges also became more difficult as the participants got fitter.
Thanks to these motivating elements, the participants faithfully complied with the cycling exercise regime three times a week for 6 months. After the study, the cycling patients had a significantly better cardiovascular fitness, which has many obvious advantages.
Useful addition to medicationThe motor disability of the cycling group was also significantly better: according to the gold standard (the MDS-UPDRS score), the cycling group scored on average 4.2 points lower than the control group. This is a rather large effect, comparable to that of several conventional Parkinson's drugs. PhD candidate Nicolien van der Kolk: "We were pleasantly surprised that people with Parkinson's disease were able to adhere to their exercise regimes so well. The beneficial effect on their motor disability was also large enough to be clinically relevant. As such, exercise is a very useful addition to the medication.”
The fact that this cycling exercise can take place entirely at home is a major advantage for patients, as this greatly enhances the feasibility of the treatment. Principal investigator Professor Bas Bloem: “This study is very important. We can now start researching whether much more long-term cycling can also slow the disease progression. Also, this new ‘exergaming’ approach that we have developed is very suitable to achieve long-term improvements in exercise behavior for patients with a range of other disorders that could also benefit from regular exercise.”
Related news items
Nijmegen literally puts Digital Health on the map Flourishing ecosystem gets its own interactive overview22 July 2021
Digital Health is thriving in the Nijmegen region, where it contributes to better care and health and also creates jobs. To bring developers and end users even closer together, The Economic Board and the Radboudumc are introducing the Interactive Digital Health map.read more
Michiel Vermeulen and Klaas Mulder receive funding from ZonMw for a collaborative project using stem cell-based models15 July 2021
Michiel Vermeulen and Klaas Mulder, theme Cancer development and immune defense, receive funding from ZonMw for a collaborative project to develop a stem cell based model to study early human embryogenesis.read more
Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development15 July 2021
The partnership will accelerate the development of new Tuberculosis (TB) drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development Consortiumread more